Literature DB >> 19801725

[The anti-tubercular drugs in the treatment of psoriasis].

N V Tsiskarishvili, N I Tsiskarishvili.   

Abstract

Psoriasis - systemic disease, including complex of interdependent pathogenetic links, which attach great importance to immunological disorders. According to recent years, the basis of the pathogenesis of psoriasis is the migration of T-lymphocytes from the blood into the skin, where they activate and start a cascade release of proinflammatory cytokines. The aim of the study was the assessment of therapeutic effectiveness of the phased application of Rifampicin and electropulse therapy in the treatment of patients with psoriasis. Under observation were 25 patients with vulgar psoriasis (13 women and 12 men aged from 18 to 65 years, with duration of illness from 1 month to 25 years). Rifampicin was prescribed to a daily dose of 600 mg for 60 days. Topical therapy was limited by the use of emollients. During the sessions of electropulse therapy the apparatus of elctronarcosis has been used. The state of the patients assessed 2 times a month. The effectiveness of treatment in patients receiving Rifampicin was the same regardless of the presence or absence of concomitant bacterial infection, which suggests that the positive therapeutic results of rifampicin is related not to its antibacterial, but to immunomodulatory effects. As a conclusion we can say that, the application of electropulse therapy and Rifampicin phase-treatment in patients with psoriasis reduces the period of the normalization of clinical indices for 7 days, as well as 2,5 times reduces the frequency of relapses in the year.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801725

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  3 in total

Review 1.  Rifampicin and Parkinson's disease.

Authors:  Wei Bi; Lihong Zhu; Xiuna Jing; Yanran Liang; Enxiang Tao
Journal:  Neurol Sci       Date:  2012-07-21       Impact factor: 3.307

2.  Inhibition of 26S protease regulatory subunit 7 (MSS1) suppresses neuroinflammation.

Authors:  Wei Bi; Xiuna Jing; Lihong Zhu; Yanran Liang; Jun Liu; Lianhong Yang; Songhua Xiao; Anding Xu; Qiaoyun Shi; Enxiang Tao
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

3.  Rifampicin attenuates experimental autoimmune encephalomyelitis by inhibiting pathogenic Th17 cells responses.

Authors:  Ke Ma; Xi Chen; Jia-Cheng Chen; Ying Wang; Xi-Meng Zhang; Fan Huang; Jun-Jiong Zheng; Xiong Chen; Wei Yu; Ke-Ling Cheng; Yan-Qing Feng; Huai-Yu Gu
Journal:  J Neurochem       Date:  2016-11-29       Impact factor: 5.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.